2010;304:1073– 81. Syne qua non study no: TAX12001 Targovax study no: CT TG01 -01 Page 1 of 5 Date: 04OCT2018 Version: Final 1.0 ST/form/038/1 A Phase I/II Trial of TG01 and Gemcitabine as Adjuvant Therapy for Treating Patients with Resected Adenocarcinoma of the Pancreas Targovax ASA Study No: CT TG01 -01 Syne qua non Ltd Study No: TAX12001 Statistical Analysis Plan Addendum Version: Final 1.0 Date: 04 October 2018 For Syne qua non Ltd – Lead Statistician For Targovax ASA If signing manually, please include: Signature + Date + Full Name + Position Syne qua non study no: TAX12001 Targovax study no: CT TG01 -01 Page 2 of 5 Date: 04OCT2018 Version: Final 1.0 ST/form/038/1 Contents 1 INTRODUCTION ............................................................................................................................. 4 2 CHANGES TO the FINAL SAP .......................................................................................................